Daniel Joseph McCarthy - 15 Nov 2023 Form 4 Insider Report for Evolent Health, Inc. (EVH)

Role
PRESIDENT
Signature
/s/ Jonathan Weinberg. Attorney-in-fact
Issuer symbol
EVH
Transactions as of
15 Nov 2023
Net transactions value
-$298,050
Form type
4
Filing time
20 Nov 2023, 08:01:03 UTC
Previous filing
14 Jun 2023
Next filing
26 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVH Class A Common Stock Sale $120,000 -4,000 -1.9% $30.00 202,333 15 Nov 2023 Direct F1, F2
transaction EVH Class A Common Stock Sale $120,000 -4,000 -2% $30.00 198,333 15 Nov 2023 Direct F1, F2
transaction EVH Class A Common Stock Options Exercise $31,950 +3,000 +1.5% $10.65 201,333 15 Nov 2023 Direct F1, F2
transaction EVH Class A Common Stock Sale $90,000 -3,000 -1.5% $30.00 198,333 15 Nov 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVH Class A Common Option (right to buy) Options Exercise $0 -3,000 -100% $0.000000* 0 15 Nov 2023 Class A Common Stock 3,000 $10.65 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2023.
F2 Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
F3 The Class A Common Stock Options exercised vested on May 12, 2019.